LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Novo Nordisk A-S

Chiusa

SettoreSettore sanitario

67.74 0.61

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

67.19

Massimo

68.3

Metriche Chiave

By Trading Economics

Entrata

804M

29B

Vendite

-7.6B

78B

P/E

Media del settore

19.207

50.291

EPS

6.53

Rendimento da dividendi

2.32

Margine di Profitto

37.182

Dipendenti

77,406

EBITDA

5.9B

46B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+40.74% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.32%

2.40%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

43B

309B

Apertura precedente

67.13

Chiusura precedente

67.74

Notizie sul Sentiment di mercato

By Acuity

80%

20%

359 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Novo Nordisk A-S Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 mag 2025, 11:36 UTC

Notizie principali

Novo Nordisk CEO to Step Down Amid Market Challenges

12 mag 2025, 09:36 UTC

I principali Market Mover

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 mag 2025, 11:29 UTC

Notizie principali
Utili
I principali Market Mover

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

24 giu 2025, 10:26 UTC

Discorsi di Mercato

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

23 giu 2025, 13:09 UTC

Discorsi di Mercato

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

20 giu 2025, 13:31 UTC

Acquisizioni, Fusioni, Takeovers

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

13 giu 2025, 11:39 UTC

Discorsi di Mercato

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

13 giu 2025, 10:04 UTC

Discorsi di Mercato

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

11 giu 2025, 09:45 UTC

Discorsi di Mercato

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

10 giu 2025, 13:38 UTC

Azioni calde

Stocks to Watch Tuesday: Tesla, TSMC, Novo Nordisk -- WSJ

9 giu 2025, 10:09 UTC

Discorsi di Mercato

Novo Nordisk Valuation Presents a Good Opportunity -- Market Talk

3 giu 2025, 15:03 UTC

Acquisizioni, Fusioni, Takeovers

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29 mag 2025, 01:00 UTC

Notizie principali

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20 mag 2025, 14:08 UTC

Utili

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20 mag 2025, 07:43 UTC

Discorsi di Mercato

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16 mag 2025, 18:35 UTC

Notizie principali

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mag 2025, 17:34 UTC

Notizie principali

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16 mag 2025, 13:42 UTC

Azioni calde

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 mag 2025, 13:27 UTC

Discorsi di Mercato

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16 mag 2025, 13:15 UTC

Notizie principali

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16 mag 2025, 12:17 UTC

Utili

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12 mag 2025, 22:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mag 2025, 18:45 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mag 2025, 12:07 UTC

Discorsi di Mercato

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mag 2025, 07:20 UTC

Discorsi di Mercato

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 mag 2025, 15:13 UTC

Utili

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 mag 2025, 13:56 UTC

Utili

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mag 2025, 13:45 UTC

Utili

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 mag 2025, 11:25 UTC

Utili

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 mag 2025, 11:18 UTC

Utili

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Novo Nordisk A-S Previsione

Obiettivo di Prezzo

By TipRanks

40.74% in crescita

Previsioni per 12 mesi

Media 94.79 USD  40.74%

Alto 142.564 USD

Basso 61 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novo Nordisk A-S - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

4

Acquista

3

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

62.63 / 69.23Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

359 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.